Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation - PubMed (original) (raw)

Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation

J I Cohen et al. J Virol. 1991 May.

Abstract

Epstein-Barr virus (EBV) nuclear protein 2 (EBNA-2) is essential for B-lymphocyte growth transformation. EBNA-2 transactivates expression of the EBV latent membrane protein (LMP-1) and also transactivates expression of the B-lymphocyte proteins CD21 and CD23. In order to analyze the functional domains of EBNA-2, we constructed 11 linker-insertion and 15 deletion mutations. Each of the mutant EBNA-2 proteins localized to the nucleus, and each was expressed at levels similar to wild-type EBNA-2. Deletion of both EBNA-2 basic domains was required to prevent nuclear localization, indicating that either is sufficient for nuclear translocation. The mutant EBNA-2 genes were assayed for lymphocyte transformation after recombination with the EBNA-2-deleted P3HR-1 EBV genome and for LMP-1 transactivation following transfection into P3HR-1-infected B-lymphoma cells. Cell lines transformed by recombinant EBV carrying EBNA-2 mutations were assayed for growth properties and LMP-1, CD21, and CD23 expression. The mutational analysis indicates that at least four separate EBNA-2 domains are essential for lymphocyte transformation. Two other domains are necessary for the full transforming phenotype. Two deletion and eight linker-insertion mutations did not reduce transforming activity. Mutations which diminish or abolish lymphocyte transformation also diminish or abolish LMP-1 transactivation, respectively. Cells transformed by recombinant EBV carrying EBNA-2 genes with diminished or normal transforming activity all expressed high levels of LMP-1, CD23, and CD21. These findings suggest that transactivation of these viral and cellular genes by EBNA-2 plays a critical role in lymphocyte transformation by EBV. Furthermore, these results indicate that the transformation and transactivation functions of EBNA-2 may not be separable.

PubMed Disclaimer

Similar articles

• Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
  Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E. Wang F, et al. J Virol. 1990 May;64(5):2309-18. doi: 10.1128/JVI.64.5.2309-2318.1990. J Virol. 1990. PMID: 2157887 Free PMC article.
• Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element.
  Wang F, Kikutani H, Tsang SF, Kishimoto T, Kieff E. Wang F, et al. J Virol. 1991 Aug;65(8):4101-6. doi: 10.1128/JVI.65.8.4101-4106.1991. J Virol. 1991. PMID: 1649318 Free PMC article.
• Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
  Cordier M, Calender A, Billaud M, Zimber U, Rousselet G, Pavlish O, Banchereau J, Tursz T, Bornkamm G, Lenoir GM. Cordier M, et al. J Virol. 1990 Mar;64(3):1002-13. doi: 10.1128/JVI.64.3.1002-1013.1990. J Virol. 1990. PMID: 2154588 Free PMC article.
• Immortalizing genes of Epstein-Barr virus.
  Middleton T, Gahn TA, Martin JM, Sugden B. Middleton T, et al. Adv Virus Res. 1991;40:19-55. doi: 10.1016/s0065-3527(08)60276-6. Adv Virus Res. 1991. PMID: 1659776 Review.
• Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1.
  Kis LL, Takahara M, Nagy N, Klein G, Klein E. Kis LL, et al. Immunol Lett. 2006 Apr 15;104(1-2):83-8. doi: 10.1016/j.imlet.2005.11.003. Epub 2005 Dec 1. Immunol Lett. 2006. PMID: 16386314 Review.

Cited by

• An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator.
  Cohen JI, Kieff E. Cohen JI, et al. J Virol. 1991 Nov;65(11):5880-5. doi: 10.1128/JVI.65.11.5880-5885.1991. J Virol. 1991. PMID: 1656076 Free PMC article.
• BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication.
  Marchini A, Tomkinson B, Cohen JI, Kieff E. Marchini A, et al. J Virol. 1991 Nov;65(11):5991-6000. doi: 10.1128/JVI.65.11.5991-6000.1991. J Virol. 1991. PMID: 1656084 Free PMC article.
• The EBNA2-related resistance towards alpha interferon (IFN-alpha) in Burkitt's lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3.
  Kanda K, Decker T, Aman P, Wahlström M, von Gabain A, Kallin B. Kanda K, et al. Mol Cell Biol. 1992 Nov;12(11):4930-6. doi: 10.1128/mcb.12.11.4930-4936.1992. Mol Cell Biol. 1992. PMID: 1406670 Free PMC article.
• Protein kinase A associates with HA95 and affects transcriptional coactivation by Epstein-Barr virus nuclear proteins.
  Han I, Xue Y, Harada S, Orstavik S, Skalhegg B, Kieff E. Han I, et al. Mol Cell Biol. 2002 Apr;22(7):2136-46. doi: 10.1128/MCB.22.7.2136-2146.2002. Mol Cell Biol. 2002. PMID: 11884601 Free PMC article.
• The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE.
  Tong X, Drapkin R, Yalamanchili R, Mosialos G, Kieff E. Tong X, et al. Mol Cell Biol. 1995 Sep;15(9):4735-44. doi: 10.1128/MCB.15.9.4735. Mol Cell Biol. 1995. PMID: 7651391 Free PMC article.

References

1. 1. Nature. 1989 Aug 3;340(6232):393-7 - PubMed
2. 1. J Virol. 1986 Aug;59(2):453-62 - PubMed
3. 1. Cell. 1988 Jul 15;54(2):275-83 - PubMed
4. 1. Oncogene. 1988 May;2(5):461-7 - PubMed
5. 1. J Virol. 1988 Nov;62(11):4173-84 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central